Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Nivolumab for CCA

Richard D. Kim • 3 Jul 2020
ESMO WCGIC 2020
Bile Duct Cancer Gastrointestinal Cancer Antibodies FOLFOX Nivolumab
ABC-06

Richard Kim, MD, of the Moffitt Cancer Center, Tampa, FL, describes Phase II results of nivolumab in patients with advanced, refractory cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Richard D. Kim

2:15
The role of immunotherapy in cholangiocarcinoma
Richard D. Kim et al. • 26 Jan 2023
2:40
Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer
Richard D. Kim et al. • 26 Jan 2023
1:55
The latest in targeted therapies for advanced colorectal cancer
Richard D. Kim et al. • 26 Jan 2023
2:44
Biomarkers of treatment response in patients with MMR-proficient CRC
Richard D. Kim et al. • 26 Jan 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals